Back to results
US 2025/0205337 A1Published application
Compositions and methods for activating immune cells
AssigneeMDX Management LLC
InventorsYuan LIU, Zhen BIAN, Lei SHI, Harry STYLLI
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMDX Management LLC
InventorsYuan LIU, Zhen BIAN, Lei SHI, Harry STYLLI
Estimating the term…
The present application provides compositions and methods for producing antigen presenting cells (APCs) from monocytes (e.g., monocytes from cancer patients) that involve an IL-10 receptor activator (e.g., IL-10), IFNγ receptor activator (e.g., IFNγ), TNFα receptor activator (e.g., TNFα), IL-4 receptor activator (e.g., IL-4), GM-CSF receptor activator (e.g., GM-CSF), and/or IL-6 receptor activator (e.g., IL-6). APCs produced accordingly are also provided, as well as methods of activating immune cells (e.g., T cells) via co-culturing with APCs. The activated immune cell compositions and the methods of treatments that involve the activated immune cells are also provided.
A method of stimulating a population of monocytes from an individual to produce a population of antigen presenting cells (“APCs”), comprising contacting the population of monocytes with a plurality of survival, differentiation and/or maturation factors (“S/D/M factors”) separately or simultaneously,
A method of promoting the survival of a population of monocytes from an individual in an in vitro culture, comprising cultivating the population of monocytes in a medium having an IL-10R activator, optionally wherein the IL-10R activator is selected from the group consisting of:
A method of promoting the survival of a population of monocytes from an individual in an in vitro culture, comprising cultivating the population of monocytes in a medium having one or more molecules that promote IL-10 receptor (IL-10R) expression on the monocytes.
A method of increasing expression of IL-10 receptor (IL-10R) in a population of monocytes from an individual having cancer, comprising contacting the population of monocytes with one or more agents selected from the group consisting of:
A method of promoting the survival of a population of monocytes from an individual in an in vitro culture, comprising cultivating the population of monocytes in a medium comprising IL-10, TNFα, and IFNγ.
A method of promoting the differentiation of a population of monocytes from an individual to antigen presenting cells (“APCs”) in an in vitro culture, comprising cultivating the population of monocytes in a medium having one or more molecules selected from the group consisting of an IL-4 receptor (IL-4R) activator, a TNFα receptor (TNFR) activator, and an interferon γ (IFNγ) receptor (IFNGR) activator.
A population of APCs, wherein the APCs a) are MHC-I+/high, MHC-II+/high, and CD40+/high, b) are TLR2+/high and/or STING+/high, and c) LOX1+/high and/or uPAR+/high, and optionally wherein the expression level of CD40 on the APCs are at least 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold higher than that on monocytes, M1 macrophages, M2 macrophages, and/or MoDCs.
A composition comprising a plurality of survival, differentiation and/or maturation factors (“S/D/M factors”), wherein the plurality of S/D/M factors comprise:
Dependencies are inferred from the claim text.